GLAXO SMITHKLINE P chart

Last update: 2022-06-03
Key statistics and financials
Revenue per share 193.50
Dividend & Yield30.00₹ (1.98%)
Beta 0.18
Market capitalization 257.6B
Operating cash flow 8.11B
ESG Scores unknown

Company description

GlaxoSmithKline Pharmaceuticals Limited, a healthcare company, researches, develops, manufactures, and sells pharmaceutical medicines and vaccines in India and internationally. The company offers prescription and non-prescription drugs for anti-infective, gastrointestinal, nutrition, dermatology, respiratory, and rare diseases; and consumer healthcare products. It provides its product under the Augmentin, Betnovate, Calpol, Ceftum, and Synflorix brands. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was incorporated in 1924 and is headquartered in Mumbai, India.

Sector: Healthcare - Industry: Drug Manufacturers—General

Financial data

Financial Statements

Cashflow Statement 2019-03-31 2020-03-31 2021-03-31 2022-03-31
Change To Liabilities -1B -482.3M 1.07B 1.02B
Total Cashflows From Investing Activities -1.53B -568.43M 4.19B -4.05B
Net Borrowings -4.06M -150.52M -149.84M -156.1M
Total Cash From Financing Activities -3.58B -4.28B -6.96B -5.24B
Change To Operating Activities 552.66M 1.6B 850.78M -47.2M
Issuance Of Stock
Net Income 4.45B 932.05M 3.58B 16.95B
Change In Cash -1.02B 60.35M 3B -1.19B
Effect Of Exchange Rate
Total Cash From Operating Activities 4.09B 4.9B 5.78B 8.11B
Depreciation 388.38M 728.98M 702.5M 681.9M
Change To Account Receivables 268.92M -497k -999.34M 102M
Other Cashflows From Financing Activities -614.93M -737.57M -35.31M -19.9M
Change To Netincome -803.05M 2.71B 947.34M -10.72B
Capital Expenditures -2.91B -1.56B -442.27M -346.4M

Income Statement 2019-03-31 2020-03-31 2021-03-31 2022-03-31
Research Development
Income Before Tax 6.83B 3.06B 5.5B 7.79B
Net Income 4.45B 932.05M 3.58B 16.95B
Selling General Administrative 6.93B 7.74B 7.47B 6.1B
Gross Profit 17.49B 18.99B 18.65B 19.22B
Ebit 5.57B 5.87B 6.16B 6.94B
Operating Income 5.57B 5.87B 6.16B 6.94B
Interest Expense -5.54M -63.35M -35.31M -20M
Income Tax Expense 2.37B 2.13B 1.92B 3.98B
Total Revenue 31.28B 32.24B 31.99B 32.78B
Cost Of Revenue 13.79B 13.25B 13.34B 13.56B
Total Other Income ExpenseNet 1.26B -2.81B -656.04M 853.6M
Net Income From Continuing Ops 4.45B 932.05M 3.58B 3.81B
Net Income Applicable To Common Shares 4.45B 932.05M 3.58B 16.95B

Balance Sheet Statement 2019-03-31 2020-03-31 2021-03-31 2022-03-31
Total Liabilities 17.71B 13.13B 16.14B 19.7B
Total Stockholder Equity 21.4B 18.21B 14.99B 26.63B
Other Current Liabilities 9.04B 4.97B 6.47B 11.15B
Total Assets 39.11B 31.33B 31.13B 46.33B
Common Stock 1.69B 1.69B 1.69B 1.69B
Other Current Assets 1.54B 878.19M 2.64B 1.18B
Retained Earnings 19.69B 16.54B 13.35B
Treasury Stock 11.51M -28.22M -48.7M 24.94B
Cash 987.77M 1.05B 4.05B 24.85B
Total Current Liabilities 14.54B 10.22B 13.32B 16.98B
Other Stockholder Equity 11.51M -28.22M -48.7M 24.94B
Property, Plant, and Equipment 13.67B 8.27B 3.54B 3.25B
Total Current Assets 20.09B 17.75B 22.03B 37.08B
Net Tangible Assets 20.74B 17.71B 14.56B 26.28B
Net Receivables 2.1B 1.3B 2.41B 2.05B
Accounts Payable 4.06B 3.57B 4.64B 5.71B


Insider Transactions

Here are the insider transactions of stock shares related to GLAXO SMITHKLINE P:

Filer Name Transaction Text Ownership Date Filer Relation Shares
NO DATA

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to GLAXO SMITHKLINE P. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on GLAXO SMITHKLINE P

Here is the result of two systematic investment strategies applied to GLAXO SMITHKLINE P. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on GLAXO SMITHKLINE P

The following chart shows the equity curve of the two systematic investment strategies applied to GLAXO SMITHKLINE P:

GLAXO SMITHKLINE P automated entries

The systematic investment strategy that buys the first day of the month would give a performance of -18.98% on the backtest period.

Performance at glance

Performance

-18.98 %

Latent gain

-1445.35 ₹

Invested capital

7614.55 ₹

Annualized return

-4.52 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on GLAXO SMITHKLINE P

This is the result of two momentum investment strategies applied to GLAXO SMITHKLINE P. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on GLAXO SMITHKLINE P

The following chart shows all the entries opened by the momentum investment system on GLAXO SMITHKLINE P:

GLAXO SMITHKLINE P momentum entries
  • The first momentum investment strategy would give -5.83% of return on GLAXO SMITHKLINE P. That represents -572.9₹ of latent gain with 9826.7₹ of employed capital.
  • The second momentum investment strategy would give 8.39% of return on GLAXO SMITHKLINE P. That represents 716.1₹ of latent gain with 8537.7₹ of employed capital.
Performance at glance (1Q Momentum)

Performance

-5.83 %

Latent gain

-572.9 ₹

Invested capital

9826.7 ₹

Annualized return

1.52 %
Performance at glance (2Q Momentum)

Performance

8.39 %

Latent gain

716.1 ₹

Invested capital

8537.7 ₹

Annualized return

2.26 %

Momentum equity curve on GLAXO SMITHKLINE P

The following chart shows the equity curve of the two momentum strategies applied to GLAXO SMITHKLINE P:

GLAXO SMITHKLINE P momentum equity

Note: the dividends potentially given by GLAXO SMITHKLINE P are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on GLAXO SMITHKLINE P

The following chart shows the employed capital evolution of the two momentum strategies on GLAXO SMITHKLINE P since the beginning:

GLAXO SMITHKLINE P

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250₹, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000₹.


Buy the dip strategy result on GLAXO SMITHKLINE P

Buy the dip entry openings on GLAXO SMITHKLINE P

GLAXO SMITHKLINE P

The performance achieved by the robo-advisor on GLAXO SMITHKLINE P is 3.34%. That represents 99.65$ of latent gain with 2984.95₹ of employed capital. The following chart shows GLAXO SMITHKLINE P stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of GLAXO SMITHKLINE P, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

3.34 %

Latent gain

99.65 ₹

Invested capital

2984.95 ₹

Annualized return

1.52 %

Equity curve of the strategy applied to GLAXO SMITHKLINE P

The following chart shows the result of the investment strategy applied to GLAXO SMITHKLINE P:

GLAXO SMITHKLINE P

Note: the dividends potentially given by GLAXO SMITHKLINE P are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on GLAXO SMITHKLINE P

The following chart shows the employed capital evolution since the beginning of the investment strategy on GLAXO SMITHKLINE P:

GLAXO SMITHKLINE P

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on GLAXO SMITHKLINE P

In this section, I will compare the three previous investment strategies applied to GLAXO SMITHKLINE P.

Equity curve comparison on GLAXO SMITHKLINE P

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

GLAXO SMITHKLINE P investment strategy comparison

Employed capital comparison on GLAXO SMITHKLINE P

GLAXO SMITHKLINE P investment comparison

Performance comparison on GLAXO SMITHKLINE P

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment -18.98% -1445.35₹ 7614.55₹ -4.52%
Momentum 1 quarter -5.83% -572.9₹ 9826.7₹ -1.47%
Momentum 2 quarters 8.39% 716.1₹ 8537.7₹ 2.26%
Non-directional 3.34% 99.65₹ 2984.95₹ 1.52%
Annualized return comparison

Automatic investment

-4.52 %

Momentum 1Q

2.26 %

Momentum 2Q

2.26 %

Non-directional

1.52 %

Correlated stocks

Here are the most positively and negatively correlated stocks with GLAXO SMITHKLINE P:

Positive correlations

Most correlated stocks this year


Most correlated stocks last 3 months

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months

Note: The algorithm computes the probability of correlation between GLAXO SMITHKLINE P and the other stocks. There may be false positives or some missing correlated stocks. If the price of GLAXO SMITHKLINE P does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name GLAXO SMITHKLINE P
Country India
City Mumbai
Address GSK House
Phone 91 22 2495 9595
Website india-pharma.gsk.com
FullTime employees
Industry Drug Manufacturers—General
Sector Healthcare
Exchange XNSE
Ticker GLAXO.XNSE
Market

GLAXO SMITHKLINE P ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 0
Peer Environment Performance unknown
Environment Percentile unknown
Palm Oil unknown
Nuclear unknown
Fur Leather unknown
GMO unknown
Coal unknown
Pesticides unknown
Animal Testing unknown

Social scores

Social ESG Factors Scores
Social Score 0
Peer Social Performance unknown
Social Percentile unknown
Highest Controversy unknown
Peer Highest Controversy Performance unknown
Adult unknown
Gambling unknown
Alcoholic unknown
Tobacco unknown
Catholic unknown
Controversial Weapons unknown
Small Arms unknown
Military Contract unknown
Peer Count unknown

Related Controversy:


Governance scores

Governance ESG Factors Scores
Governance Score 0
Peer Governance Performance unknown
Governance Percentile unknown

ESG at glance
Total ESG Scores: unknown
Environment Score: 0
Social Score: 0
Governance Score: 0

ESG Performance: unknown

Peer Group: unknown

Peer Esg Score Performance: unknown

Rating Year: unknown

Rating Month: unknown

Max Age: unknown

Percentile: unknown